Asia-Pacific Tumor Biomarker Test Market Report 2018

Table of Contents

1 Report Overview

• 1.1 Definition and Specification
• 1.2 Report Overview
  • 1.2.1 Manufacturers Overview
  • 1.2.2 Regions Overview
  • 1.2.3 Type Overview
  • 1.2.4 Application Overview
• 1.3 Industrial Chain
  • 1.3.1 Tumor Biomarker Test Overall Industrial Chain
  • 1.3.2 Upstream
  • 1.3.3 Downstream
• 1.4 Industry Situation
  • 1.4.1 Industrial Policy
  • 1.4.2 Product Preference
  • 1.4.3 Economic/Political Environment
• 1.5 SWOT Analysis

2 Market Analysis by Types

• 2.1 Overall Market Performance(Volume)
  • 2.1.1 Prostate Specific Antigen Tests Market Performance (Volume)
  • 2.1.2 CTC Tests Market Performance (Volume)
  • 2.1.3 Alpha-Fetoprotein (AFP) Tests Market Performance (Volume)
  • 2.1.4 CA Test Market Performance (Volume)
  • 2.1.5 HER2 Tests Market Performance (Volume)
• 2.2 Overall Market Performance(Value)
  • 2.1.1 Prostate Specific Antigen Tests Market Performance (Value)
  • 2.1.2 CTC Tests Market Performance (Value)
  • 2.1.3 Alpha-Fetoprotein (AFP) Tests Market Performance (Value)
  • 2.1.4 CA Test Market Performance (Value)
  • 2.1.5 HER2 Tests Market Performance (Value)

3 Product Application Market

• 3.1 Overall Market Performance (Volume)
  • 3.1.1 Lung cancer Market Performance (Volume)
  • 3.1.2 Breast cancer Market Performance (Volume)
  • 3.1.3 Colorectal Market Performance (Volume)
  • 3.1.4 Prostate Cancer Market Performance (Volume)
  • 3.1.5 Blood Cancer Market Performance (Volume)

4 Manufacturers Profiles/Analysis

• 4.1 Abbott Laboratories, Inc.
  • 4.1.1 Abbott Laboratories, Inc. Profiles
  • 4.1.2 Abbott Laboratories, Inc. Product Information
  • 4.1.3 Abbott Laboratories, Inc. Tumor Biomarker Test Business Performance
  • 4.1.4 Abbott Laboratories, Inc. Tumor Biomarker Test Business Development and Market Status
• 4.2 Agilent Technologies
  • 4.2.1 Agilent Technologies Profiles
  • 4.2.2 Agilent Technologies Product Information
  • 4.2.3 Agilent Technologies Tumor Biomarker Test Business Performance
  • 4.2.4 Agilent Technologies Tumor Biomarker Test Business Development and Market Status
• 4.3 AstraZeneca
  • 4.3.1 AstraZeneca Profiles
  • 4.3.2 AstraZeneca Product Information
  • 4.3.3 AstraZeneca Tumor Biomarker Test Business Performance
  • 4.3.4 AstraZeneca Tumor Biomarker Test Business Development and Market Status
• 4.4 Becton Dickinson & Co.
  • 4.4.1 Becton Dickinson & Co. Profiles
  • 4.4.2 Becton Dickinson & Co. Product Information
  • 4.4.3 Becton Dickinson & Co. Tumor Biomarker Test Business Performance
  • 4.4.4 Becton Dickinson & Co. Tumor Biomarker Test Business Development and Market Status
• 4.5 Biocept Inc.
  • 4.5.1 Biocept Inc. Profiles
  • 4.5.2 Biocept Inc. Product Information
  • 4.5.3 Biocept Inc. Tumor Biomarker Test Business Performance
  • 4.5.4 Biocept Inc. Tumor Biomarker Test Business Development and Market Status
• 4.6 Cancer Genetics Inc.
  • 4.6.1 Cancer Genetics Inc. Profiles
  • 4.6.2 Cancer Genetics Inc. Product Information
  • 4.6.3 Cancer Genetics Inc. Tumor Biomarker Test Business Performance
  • 4.6.4 Cancer Genetics Inc. Tumor Biomarker Test Business Development and Market Status
• 4.7 Danaher Corporation
  • 4.7.1 Danaher Corporation Profiles
  • 4.7.2 Danaher Corporation Product Information
  • 4.7.3 Danaher Corporation Tumor Biomarker Test Business Performance
  • 4.7.4 Danaher Corporation Tumor Biomarker Test Business Development and Market Status
• 4.8 Foundation Medicine Inc.
  • 4.8.1 Foundation Medicine Inc. Profiles
  • 4.8.2 Foundation Medicine Inc. Product Information
  • 4.8.3 Foundation Medicine Inc. Tumor Biomarker Test Business Performance
  • 4.8.4 Foundation Medicine Inc. Tumor Biomarker Test Business Development and Market Status
• 4.9 Illumina Inc.
  • 4.9.1 Illumina Inc. Profiles
  • 4.9.2 Illumina Inc. Product Information
  • 4.9.3 Illumina Inc. Tumor Biomarker Test Business Performance
  • 4.9.4 Illumina Inc. Tumor Biomarker Test Business Development and Market Status
• 4.10 LabCorp Of America Holdings
  • 4.10.1 LabCorp Of America Holdings Profiles
  • 4.10.2 LabCorp Of America Holdings Product Information
  • 4.10.3 LabCorp Of America Holdings Tumor Biomarker Test Business Performance
  • 4.10.4 LabCorp Of America Holdings Tumor Biomarker Test Business Development and Market Status
• 4.11 Luminex Corporation
• 4.12 Myriad Genetics Inc.
• 4.13 AstraZeneca

5 Market Performance for Manufacturers

• 5.1 Asia-Pacific Tumor Biomarker Test Sales (K Units) and Market Share by Manufacturers 2013-2018
• 5.2 Asia-Pacific Tumor Biomarker Test Revenue (M USD) and Market Share by Manufacturers 2013-2018
• 5.3 Asia-Pacific Tumor Biomarker Test Price (USD/Unit) of Manufacturers 2013-2018
• 5.4 Asia-Pacific Tumor Biomarker Test Gross Margin of Manufacturers 2013-2018
• 5.5 Market Concentration

6 Regions Market Performance for Manufacturers

• 6.1 China Market Performance for Manufacturers
  • 6.1.1 China Tumor Biomarker Test Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.1.2 China Tumor Biomarker Test Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.1.3 China Tumor Biomarker Test Price (USD/Unit) of Manufacturers 2013-2018
  • 6.1.4 China Tumor Biomarker Test Gross Margin of Manufacturers 2013-2018
  • 6.1.5 Market Concentration
• 6.2 Japan Market Performance for Manufacturers
  • 6.2.1 Japan Tumor Biomarker Test Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.2.2 Japan Tumor Biomarker Test Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.2.3 Japan Tumor Biomarker Test Price (USD/Unit) of Manufacturers 2013-2018
  • 6.2.4 Japan Tumor Biomarker Test Gross Margin of Manufacturers 2013-2018
  • 6.2.5 Market Concentration
• 6.3 South Korea Market Performance for Manufacturers
  • 6.3.1 South Korea Tumor Biomarker Test Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.3.2 South Korea Tumor Biomarker Test Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.3.3 South Korea Tumor Biomarker Test Price (USD/Unit) of Manufacturers 2013-2018
  • 6.3.4 South Korea Tumor Biomarker Test Gross Margin of Manufacturers 2013-2018
  • 6.3.5 Market Concentration
• 6.4 Taiwan Market Performance for Manufacturers
  • 6.4.1 Taiwan Tumor Biomarker Test Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.4.2 Taiwan Tumor Biomarker Test Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.4.3 Taiwan Tumor Biomarker Test Price (USD/Unit) of Manufacturers 2013-2018
  • 6.4.4 Taiwan Tumor Biomarker Test Gross Margin of Manufacturers 2013-2018
  • 6.4.5 Market Concentration
• 6.5 India Market Performance for Manufacturers
  • 6.5.1 India Tumor Biomarker Test Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.5.2 India Tumor Biomarker Test Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.5.3 India Tumor Biomarker Test Price (USD/Unit) of Manufacturers 2013-2018
  • 6.5.4 India Tumor Biomarker Test Gross Margin of Manufacturers 2013-2018
  • 6.5.5 Market Concentration
• 6.6 Southeast Asia Market Performance for Manufacturers
  • 6.6.1 Southeast Asia Tumor Biomarker Test Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.6.2 Southeast Asia Tumor Biomarker Test Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.6.3 Southeast Asia Tumor Biomarker Test Price (USD/Unit) of Manufacturers 2013-2018
  • 6.6.4 Southeast Asia Tumor Biomarker Test Gross Margin of Manufacturers 2013-2018
  • 6.6.5 Market Concentration
• 6.7 Australia Market Performance for Manufacturers
  • 6.7.1 Australia Tumor Biomarker Test Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.7.2 Australia Tumor Biomarker Test Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.7.3 Australia Tumor Biomarker Test Price (USD/Unit) of Manufacturers 2013-2018
  • 6.7.4 Australia Tumor Biomarker Test Gross Margin of Manufacturers 2013-2018
  • 6.7.5 Market Concentration
• 6.8 Market Performance for Manufacturers
  • 6.8.1 Tumor Biomarker Test Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.8.2 Tumor Biomarker Test Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.8.3 Tumor Biomarker Test Price (USD/Unit) of Manufacturers 2013-2018
  • 6.8.4 Tumor Biomarker Test Gross Margin of Manufacturers 2013-2018
  • 6.8.5 Market Concentration

7 Asia-Pacific Tumor Biomarker Test Market Performance (Sales Point)

• 7.1 Asia-Pacific Tumor Biomarker Test Sales (K Units) and Market Share by Regions 2013-2018
• 7.2 Asia-Pacific Tumor Biomarker Test Revenue (M USD) and Market Share by Regions 2013-2018
• 7.3 Asia-Pacific Tumor Biomarker Test Price (USD/Unit) by Regions 2013-2018
• 7.4 Asia-Pacific Tumor Biomarker Test Gross Margin by Regions 2013-2018

8 Development Trend for Regions (Sales Point)

• 8.1 Asia-Pacific Tumor Biomarker Test Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.2 China Tumor Biomarker Test Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.3 Japan Tumor Biomarker Test Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.4 South Korea Tumor Biomarker Test Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.5 Taiwan Tumor Biomarker Test Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.6 India Tumor Biomarker Test Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.7 Southeast Asia Tumor Biomarker Test Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Australia Tumor Biomarker Test Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Australia Tumor Biomarker Test Sales and Growth, Sales Value and Growth Rate2013-2018

9 Upstream Source, Technology and Cost

• 9.1 Upstream Source
• 9.2 Technology
• 9.3 Cost

10 Channel Analysis

• 10.1 Market Channel
• 10.2 Distributors

11 Consumer Analysis

• 11.1 Lung cancer Industry
• 11.2 Breast cancer Industry
• 11.3 Colorectal Industry

12 Market Forecast 2019-2024

• 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
  • 12.1.1 Asia-Pacific Tumor Biomarker Test Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
  • 12.1.2 Asia-Pacific Tumor Biomarker Test Sales (K Units) and Growth Rate 2019-2024
  • 12.1.3 China Tumor Biomarker Test Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.4 Japan Tumor Biomarker Test Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.5 South Korea Tumor Biomarker Test Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.6 Taiwan Tumor Biomarker Test Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.7 India Tumor Biomarker Test Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.8 Southeast Asia Tumor Biomarker Test Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.9 Australia Tumor Biomarker Test Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.10 Tumor Biomarker Test Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
  • 12.3.1 Overall Market Performance
  • 12.3.2 Prostate Specific Antigen Tests Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.3 CTC Tests Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.4 Alpha-Fetoprotein (AFP) Tests Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.5 CA Test Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.4 Sales by Application 2019-2024
  • 12.4.1 Overall Market Performance
  • 12.4.2 Lung cancer Sales and and Growth Rate 2019-2024
  • 12.4.3 Breast cancer Sales and and Growth Rate 2019-2024
  • 12.4.4 Colorectal Sales and and Growth Rate 2019-2024
  • 12.4.5 Prostate Cancer Sales and and Growth Rate 2019-2024
• 12.5 Price (USD/Unit) and Gross Profit
  • 12.5.1 Asia-Pacific Tumor Biomarker Test Price (USD/Unit) Trend 2019-2024
  • 12.5.2 Asia-Pacific Tumor Biomarker Test Gross Profit Trend 2019-2024

13 Conclusion